参考文献/References:
[1] Karamitanha F,Ahmadi F,Fallahabadi H. Difference between various countries in mortality and incidence rate of the atrial fibrillation based on human development index in worldwide:data from global burden of disease 2010-2019[J]. Curr Probl Cardiol,2023,48(1):101438.
[2] Schnabel RB,Yin X,Gona P,et al. 50 year trends in atrial fibrillation prevalence, incidence,risk factors,and mortality in the Framingham Heart Study:a cohort study[J]. Lancet,2015,386(9989):154-162.
[3] Chung MK,Refaat M,Shen WK,et al. Atrial fibrillation:JACC council perspectives[J]. J Am Coll Cardiol,2020,75(14):1689- 1713.
[4] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[5] Shi S,Tang Y,Zhao Q,et al. Prevalence and risk of atrial fibrillation in China:a national cross-sectional epidemiological study[J]. Lancet Reg Health West Pac,2022,23:100439.
[6] Song J. The Chinese burden of atrial fibrillation review of atrial fibrillation studies in China[J]. Ann Noninvasive Electrocardiol,2022,27(6):e12957.
[7] Zhang J,Johnsen SP,Guo Y,et al. Epidemiology of atrial fibrillation:geographic/ecological risk factors,age,sex,genetics[J]. Card Electrophysiol Clin,2021,13(1):1-23.
[8] Wang Z,Chen Z,Wang X,et al. The disease burden of atrial fibrillation in china from a national cross-sectional survey[J]. Am J Cardiol,2018,122(5):793-798.
[9] Li H,S ong X,L iang Y,et al. Global,regional,and national burden of disease study of atrial fibrillation/flutter,1990 -2019:results from a global burden of disease study,2019[J]. BMC Public Health,2022,22(1):2015.
[10] Bai Y,Wang YL,Shantsila A,et al. The global burden of atrial fibrillation and?stroke:a systematic review of the clinical epidemiology of atrial fibrillation in Asia[J]. Chest,2017,152(4):810-820.
[11] Seshadri S,Wolf PA. Lifetime risk of stroke and dementia:current concepts, and estimates from the Framingham study[J]. Lancet Neurol,2007,6(12):1106-1114.
[12] Guo Y,Tian Y,Wang H,et al. Prevalence,incidence,and lifetime risk of atrial fibrillation in China:new insights into the global burden of atrial fibrillation[J]. Chest,2015,147(1):109-119.
[13] Virani SS,Alonso A,Benjamin EJ,et al. Heart disease and stroke statistics—2020 update:a report from the American Heart Association[J]. Circulation,2020,141(9):e139-e596.
[14] Benjamin EJ,Wolf PA,D’Agostino RB,et al. Impact of atrial fibrillation on the risk of death:the Framingham Heart Study[J]. Circulation,1998,98(10):946-952.
[15] Lippi G,Sanchis-Goma F,Cervellin G. Global epidemiology of atrial fibrillation:an increasing epidemic and public health challenge[J]. Int J Stroke,2020,16(2):217-221.
[16] Hu K,Lou L,Tian W,et al. The outcome of breast cancer is associated with national human development index and health system attainment[J]. PloS One,2016,11(7):e0158951.
[17] 中华医学会心血管病学分会,中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志,2023,51(6):572-618.
[18] Oldgren J,H ealey JS,E zekowitz M,et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15 400 emergency department patients in 46 countries :the RE-LY atrial fibrillation registry[J]. Circulation,2014,129(15):1568-1576.
[19] Huisman MV,Rothman KJ,Paquette M,et al. The changing landscape for stroke prevention in AF:findings from the GLORIA-AF registry phase 2[J]. J Am Coll Cardiol,2017,69(7):777-785.
[20] Piccini JP,Xu H,Cox M,et al. Adherence to guideline-directed stroke prevention therapy for atrial fibrillation is achievable[J]. Circulation,2019,139(12):1497- 1506.
[21] Chen M,Li C,Liao P,et al. Epidemiology,management,and outcomes of atrial fibrillation among 30 million citizens in Shanghai,China from 2015 to 2020:a medical insurance database study[J]. Lancet Reg Health West Pac,2022,23 :100470.
[22] Xu J,Zhang X,Jin A,et al. Trends and risk factors associated with stroke recurrence in China,2007-2018[J]. JAMA Netw Open,2022,5(6):e2216341.
[23] Chan YH,Chao TF,Chen SW,et al. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants:a nationwide cohort study[J]. Eur Heart J Cardiovasc Pharmacother,2023,9(8):681-691.
[24] Guo Y,Kotalczyk A,Imberti JF,et al. Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation:a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry[J]. Eur Heart J Qual Care Clin Outcomes,2023,9(2):169-176.
[25] Bizhanov KA,Аbzaliyev KB,Baimbetov AK,et al. Atrial fibrillation:epidemiology, pathophysiology,and clinical complications (literature review)[J]. J Cardiovasc Electrophysiol,2022,34(1):153-165.
[26] Rodriguez CJ,Soliman EZ,Alonso A,et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors:the Multi-Ethnic Study of Atherosclerosis[J]. Ann Epidemiol,2015,25(2):71-76,76.e1.
[27] Norby FL,Benjamin EJ,Alonso A,et al. Racial and ethnic considerations in patients with atrial fibrillation:JACC focus seminar 5/9[J]. J Am Coll Cardiol, 2021,78(25):2563-2572.
[28] Ugowe FE,Jackson LR,Thomas KL. Racial and ethnic differences in the prevalence,management,and outcomes in patients with atrial fibrillation:a systematic review[J]. Heart Rhythm,2018,15(9):1337-1345.
[29] Essien UR,Kornej J,Johnson AE,et al. Social determinants of atrial fibrillation[J]. Nat Rev Cardiol,2021,18(11):763-773.
[30] 徐唯. 心房颤动伴合并症的预后分析及心房颤动的综合管理研究[D]. 北京:北京协和医学院,2024.
[31] Krittayaphong R,Rangsin R,Thinkhamrop B,et al. Prevalence and associating factors of atrial fibrillation in patients with hypertension:a nation-wide study[J]. BMC Cardiovasc Disord,2016,(16):57.
[32] Xing L,Lin M,Du Z,et al. Epidemiology of atrial fibrillation in northeast China:a cross-sectional study,2017-2019[J]. Heart,2020,106(8):590-595.
[33] 刘云飞. 辽宁省部分地区城乡高血压患者房颤患病现状及影响因素分析[D]. 沈阳:中国医科大学,2024.
[34] Tikhonoff V,Kuznetsova T,Thijs L,et al. Ambulatory blood pressure and long-term risk for atrial fibrillation[J]. Heart,2018,104(15):1263-1270.
[35] Davis RC,Hobbs FD,Kenkre JE,et al. Prevalence of atrial fibrillation in the general population and in high-risk groups:the ECHOES study[J]. Europace,2012,14(11):1553-1559.
[36] Lee SR,Park CS,Choi EK,et al. Hypertension burden and the risk of new-onset atrial fibrillation:a nationwide population-based study[J]. Hypertension,2021,77(3):919-928.
[37] Miyasaka Y,B arnes ME,G ersh BJ,et al. Incidence and mortality risk of congestive heart failure in atrial fibrillation patients:a community-based study over two decades[J]. Eur Heart J,2006,27(8):936- 941.
[38] 陈舒,刘俊,董扬. 我国心房颤动与心肌梗死、心力衰竭和全因死亡的Meta分析[J]. 心脑血管病防治,2023,23(5):54-57.
[39] 杨艳敏,张晗,朱俊. 中国急诊心房颤动注册研究:基线资料及治疗情况分析[J]. 中华心律失常学杂志,2019,23(1):12-17.
[40] Huxley RR,Alonso A,Lopez FL,et al. Type 2 diabetes,glucose homeostasis and incident atrial fibrillation:the Atherosclerosis Risk in Communities study[J]. Heart,2012,98(2):133-138.
[41] Pallisgaard JL,Schjerning AM,Lindhardt TB,et al. Risk of atrial fibrillation in diabetes mellitus:a nationwide cohort study[J]. Eur J Prev Cardiol,2016,23(6):621-627.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(7):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(7):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(7):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(7):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(7):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]